方盛制药：公司相关生产线通过药品GMP符合性检查

Core Viewpoint - The company, Fangsheng Pharmaceutical, has successfully passed the GMP compliance inspection conducted by the Hunan Provincial Drug Administration, which is expected to enhance its production capacity and product variety to meet market demand [1] Group 1: Inspection Details - The GMP compliance inspection took place on July 8, 2025, and from July 15 to 17, 2025 [1] - The inspection covered the raw material drug workshops, specifically the production lines for Ezetimibe and Benidipine [1] - The designed production capacity for Ezetimibe raw materials is 4000 kg per year, while for Benidipine raw materials, it is 500 kg per year [1] Group 2: Compliance and Impact - The inspection results met the requirements of the Drug Administration Law, the Drug Production Supervision and Administration Measures, and the Good Manufacturing Practice (GMP) for drug production [1] - The positive inspection outcome is beneficial for the company to diversify its product offerings and maintain stable production capabilities [1] - This development is crucial for the company to satisfy market demand effectively [1]